CYTK Cytokinetics, Incorporated | US23282W6057
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 393.385.350 | 112.870.100 | 248.53% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | -4,69 | -6,31 | 25.71% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 15 | 16 | 6.25% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |